Patents by Inventor STÉPHANIE CORNEN

STÉPHANIE CORNEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KIR3DL2 BINDING AGENTS
    Publication number: 20240124579
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • KIR3DL2 binding agents
    Patent number: 11858990
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 2, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • Siglec-9-neutralizing antibodies
    Patent number: 11623954
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 11, 2023
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
  • COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
    Publication number: 20230085847
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: September 19, 2022
    Publication date: March 23, 2023
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
    Patent number: 11447545
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: September 20, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann
  • SIGLEC NEUTRALIZING ANTIBODIES
    Publication number: 20210363249
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: STEPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • Siglec-10 antibodies
    Patent number: 11083785
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 10, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Laurent Gauthier, Benjamin Rossi, Nicolai Wagtmann
  • Siglec neutralizing antibodies
    Patent number: 11078274
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: August 3, 2021
    Assignee: INNATE PHARMA
    Inventors: Stephanie Cornen, Benjamin Rossi, Nicolai Wagtmann
  • COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
    Publication number: 20200369764
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • SIGLEC-9-NEUTRALIZING ANTIBODIES
    Publication number: 20200369765
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 26, 2020
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN, LAURENT GAUTHIER
  • KIR3DL2 BINDING AGENTS
    Publication number: 20200199228
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • KIR3DL2 binding agents
    Patent number: 10577419
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: March 3, 2020
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • SIGLEC NEUTRALIZING ANTIBODIES
    Publication number: 20190085077
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: March 7, 2017
    Publication date: March 21, 2019
    Inventors: STEPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • SIGLEC-10 ANTIBODIES
    Publication number: 20180344829
    Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: November 17, 2016
    Publication date: December 6, 2018
    Inventors: STEPHANIE CORNEN, LAURENT GAUTHIER, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • CROSS REACTIVE SIGLEC ANTIBODIES
    Publication number: 20170306014
    Abstract: This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 26, 2017
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • KIR3DL2 BINDING AGENTS
    Publication number: 20150232556
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: March 19, 2015
    Publication date: August 20, 2015
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB